Neurofibromatosis Type 1 Global Market Report 2025

Description

Neurofibromatosis type 1 (NF1) is a genetic disorder that primarily impacts the nervous system, leading to the formation of benign tumors along nerves in areas such as the skin, brain, and other parts of the body. It is caused by mutations in the NF1 gene, which results in a deficiency of neurofibromin, a protein responsible for regulating cell growth. This deficiency causes a range of symptoms, including cafe-au-lait spots (light brown patches on the skin), freckling in uncommon areas, learning difficulties, skeletal issues, and, in some instances, vision or nerve-related problems.

The primary treatment for neurofibromatosis type 1 (NF1) generally involves medication, surgery, radiation therapy, and other forms of treatment. Medications used in NF1 include pharmaceutical options such as MEK inhibitors, pain relievers, and antihypertensive drugs, which help to slow tumor growth, alleviate pain, and manage associated complications. The disease encompasses conditions such as plexiform neurofibromas, cutaneous neurofibromas, optic gliomas, and others. These treatments are distributed through various channels, including hospital pharmacies, retail pharmacies, and online pharmacies, and are used by different healthcare providers, including hospitals, specialty clinics, ambulatory surgical centers, and other medical facilities.

The neurofibromatosis type 1 (NF1) market research report is one of a series of new reports from The Business Research Company that provides neurofibromatosis type 1 (NF1) market statistics, including the neurofibromatosis type 1 (NF1) industry global market size, regional shares, competitors with the neurofibromatosis type 1 (NF1) market share, detailed neurofibromatosis type 1 (NF1) market segments, market trends, and opportunities, and any further data you may need to thrive in the neurofibromatosis type 1 (NF1) industry. This neurofibromatosis type 1 (NF1) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The neurofibromatosis type 1 (NF1) market size has grown strongly in recent years. It will grow from $8.06 billion in 2024 to $8.86 billion in 2025 at a compound annual growth rate (CAGR) of 9.9%. The growth during the historical period can be credited to factors such as increased awareness, higher healthcare spending, population growth, supportive government policies, and advancements in medical infrastructure.

The neurofibromatosis type 1 (NF1) market size is expected to see strong growth in the next few years. It will grow to $12.77 billion in 2029 at a compound annual growth rate (CAGR) of 9.6%. The growth during the forecast period can be attributed to the rising number of blood cancer cases, an increase in the incidence of plexiform tumors, a higher prevalence of nerve sheath tumors, the growing occurrence of neurofibromatosis, and the expanding use of neurofibromatosis treatments. Key trends during this period include ongoing research and development, the creation of new therapies, advancements in diagnostic techniques, tumor-specific treatments, and the development of new medications.

The rise in spontaneous (de novo) mutations is expected to drive the growth of the neurofibromatosis type 1 (NF1) market. A spontaneous (de novo) mutation refers to a genetic change that occurs for the first time in an individual, due to errors during DNA replication or environmental influences, rather than being inherited from parents. The increasing occurrence of these mutations is linked to factors such as advanced parental age, environmental exposures such as radiation and chemicals, and errors in DNA replication during cell division. Neurofibromatosis type 1 (NF1) is particularly prone to de novo mutations, as the NF1 gene experiences a high mutation rate, including large deletions, insertions, or point mutations during gametogenesis. This leads to new cases of NF1 without a family history. For example, a report published in August 2023 by the journal Molecular Biology and Evolution found 534 potential de novo mutations (DNMs) in certain families. Therefore, spontaneous (de novo) mutations are contributing to the growth of the NF1 market.

Companies in the NF1 market are introducing innovative treatments, such as kinase inhibitors, to improve targeted therapy and patient outcomes. Kinase inhibitors are drugs that block the activity of kinases, enzymes responsible for transferring phosphate groups to proteins and regulating various cellular processes. In May 2023, AstraZeneca plc, a UK-based pharmaceutical company, received approval in China for Koselugo (selumetinib), a kinase inhibitor, to treat symptomatic, inoperable plexiform neurofibromas (PN) in pediatric patients with NF1, aged three years and older. This approval expands targeted treatment options for pediatric NF1 patients, improving disease management and quality of life. The introduction of Koselugo (selumetinib) in China is in line with the growing emphasis on precision medicine, providing a non-surgical option for managing inoperable plexiform neurofibromas.

In October 2022, Pasithea Therapeutics Corp., a US-based biotechnology company, acquired AlloMek Therapeutics LLC for an undisclosed amount. This acquisition aims to advance Pasithea Therapeutics' efforts in developing treatments for central nervous system disorders and other conditions, as well as establishing anti-depression clinics and offering business support services. AlloMek Therapeutics LLC is involved in developing therapeutics for catastrophic cardiomyopathy, congenital muscular diseases, and neurofibromatosis type 1, contributing to the expansion of NF1 treatment options.

Major players in the neurofibromatosis type 1 (NF1) market are Pfizer Inc., F. Hoffmann-La Roche Ltd, Merck & Co. Inc, Novartis AG, AstraZeneca Plc, Takeda Pharmaceutical Company Limited, Boehringer Ingelheim International GmbH, Vertex Pharmaceuticals Incorporated, Shanghai Fosun Pharmaceutical (Group) Co. Ltd, BeiGene Ltd., BioMarin Pharmaceutical Inc, Exelixis Inc., Blueprint Medicines Corporation, SpringWorks Therapeutics Inc, Onclive LLC, Healx Limited, Infixion Bioscience Limited, NFlection Therapeutics Inc, Pasithea Therapeutics Corporation, Mulberry Biotherapeutics Inc.

North America was the largest region in the neurofibromatosis type 1 (NF1) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in neurofibromatosis type 1 (NF1) report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the neurofibromatosis type 1 (NF1) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The neurofibromatosis type 1 (NF1) market consists of revenues earned by entities by providing services such as medical monitoring, genetic counselling, and specialized care. The market value includes the value of related goods sold by the service provider or included within the service offering. The neurofibromatosis type 1 (NF1) market also includes sales of medical devices, MEK inhibitors, anticonvulsants, and analgesics. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Neurofibromatosis Type 1 Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on neurofibromatosis type 1 market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for neurofibromatosis type 1 ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The neurofibromatosis type 1 market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:1) By Treatment: Medication; Surgery; Radiation Therapy; Other Treatments
2) By Disease Type: Plexiform Neurofibromas; Cutaneous Neurofibromas; Optic Gliomas; Other Diseases
3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
4) By End Users: Hospitals; Speciality Clinics; Ambulatory Surgical Centers; Other End Users
Subsegments:
1) By Medication: Targeted Therapy; Pain Management Medications; Anticonvulsants
2) By Surgery: Tumor Removal Surgery; Nerve Decompression Surgery
3) By Radiation Therapy: Stereotactic Radiosurgery; External Beam Radiation Therapy
4) By Other Treatments: Physical Therapy; Genetic Counseling; Psychological Support And Counseling
Companies Mentioned: Pfizer Inc.; F. Hoffmann-La Roche Ltd; Merck & Co. Inc; Novartis AG; AstraZeneca Plc
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery format: PDF, Word and Excel Data Dashboard.

Product Code: r34096

1. Executive Summary

2. Neurofibromatosis Type 1 Market Characteristics

3. Neurofibromatosis Type 1 Market Trends And Strategies

4. Neurofibromatosis Type 1 Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Neurofibromatosis Type 1 Growth Analysis And Strategic Analysis Framework

5.1. Global Neurofibromatosis Type 1 PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Neurofibromatosis Type 1 Market Growth Rate Analysis
5.4. Global Neurofibromatosis Type 1 Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Neurofibromatosis Type 1 Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Neurofibromatosis Type 1 Total Addressable Market (TAM)

6. Neurofibromatosis Type 1 Market Segmentation

6.1. Global Neurofibromatosis Type 1 Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Medication
Surgery
Radiation Therapy
Other Treatments
6.2. Global Neurofibromatosis Type 1 Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Plexiform Neurofibromas
Cutaneous Neurofibromas
Optic Gliomas
Other Diseases
6.3. Global Neurofibromatosis Type 1 Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
6.4. Global Neurofibromatosis Type 1 Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospitals
Speciality Clinics
Ambulatory Surgical Centers
Other End Users
6.5. Global Neurofibromatosis Type 1 Market, Sub-Segmentation Of Medication, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Targeted Therapy
Pain Management Medications
Anticonvulsants
6.6. Global Neurofibromatosis Type 1 Market, Sub-Segmentation Of Surgery, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Tumor Removal Surgery
Nerve Decompression Surgery
6.7. Global Neurofibromatosis Type 1 Market, Sub-Segmentation Of Radiation Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Stereotactic Radiosurgery
External Beam Radiation Therapy
6.8. Global Neurofibromatosis Type 1 Market, Sub-Segmentation Of Other Treatments, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Physical Therapy
Genetic Counseling
Psychological Support And Counseling

7. Neurofibromatosis Type 1 Market Regional And Country Analysis

7.1. Global Neurofibromatosis Type 1 Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Neurofibromatosis Type 1 Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Neurofibromatosis Type 1 Market

8.1. Asia-Pacific Neurofibromatosis Type 1 Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Neurofibromatosis Type 1 Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Neurofibromatosis Type 1 Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Neurofibromatosis Type 1 Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Neurofibromatosis Type 1 Market

9.1. China Neurofibromatosis Type 1 Market Overview
9.2. China Neurofibromatosis Type 1 Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Neurofibromatosis Type 1 Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Neurofibromatosis Type 1 Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Neurofibromatosis Type 1 Market

10.1. India Neurofibromatosis Type 1 Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Neurofibromatosis Type 1 Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Neurofibromatosis Type 1 Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Neurofibromatosis Type 1 Market

11.1. Japan Neurofibromatosis Type 1 Market Overview
11.2. Japan Neurofibromatosis Type 1 Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Neurofibromatosis Type 1 Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Neurofibromatosis Type 1 Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Neurofibromatosis Type 1 Market

12.1. Australia Neurofibromatosis Type 1 Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Neurofibromatosis Type 1 Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Neurofibromatosis Type 1 Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Neurofibromatosis Type 1 Market

13.1. Indonesia Neurofibromatosis Type 1 Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Neurofibromatosis Type 1 Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Neurofibromatosis Type 1 Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Neurofibromatosis Type 1 Market

14.1. South Korea Neurofibromatosis Type 1 Market Overview
14.2. South Korea Neurofibromatosis Type 1 Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Neurofibromatosis Type 1 Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Neurofibromatosis Type 1 Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Neurofibromatosis Type 1 Market

15.1. Western Europe Neurofibromatosis Type 1 Market Overview
15.2. Western Europe Neurofibromatosis Type 1 Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Neurofibromatosis Type 1 Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Neurofibromatosis Type 1 Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Neurofibromatosis Type 1 Market

16.1. UK Neurofibromatosis Type 1 Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Neurofibromatosis Type 1 Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Neurofibromatosis Type 1 Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Neurofibromatosis Type 1 Market

17.1. Germany Neurofibromatosis Type 1 Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Neurofibromatosis Type 1 Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Neurofibromatosis Type 1 Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Neurofibromatosis Type 1 Market

18.1. France Neurofibromatosis Type 1 Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Neurofibromatosis Type 1 Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Neurofibromatosis Type 1 Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Neurofibromatosis Type 1 Market

19.1. Italy Neurofibromatosis Type 1 Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy Neurofibromatosis Type 1 Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy Neurofibromatosis Type 1 Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Neurofibromatosis Type 1 Market

20.1. Spain Neurofibromatosis Type 1 Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Neurofibromatosis Type 1 Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Neurofibromatosis Type 1 Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Neurofibromatosis Type 1 Market

21.1. Eastern Europe Neurofibromatosis Type 1 Market Overview
21.2. Eastern Europe Neurofibromatosis Type 1 Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Neurofibromatosis Type 1 Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Neurofibromatosis Type 1 Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Neurofibromatosis Type 1 Market

22.1. Russia Neurofibromatosis Type 1 Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Neurofibromatosis Type 1 Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Neurofibromatosis Type 1 Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Neurofibromatosis Type 1 Market

23.1. North America Neurofibromatosis Type 1 Market Overview
23.2. North America Neurofibromatosis Type 1 Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Neurofibromatosis Type 1 Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Neurofibromatosis Type 1 Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Neurofibromatosis Type 1 Market

24.1. USA Neurofibromatosis Type 1 Market Overview
24.2. USA Neurofibromatosis Type 1 Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Neurofibromatosis Type 1 Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Neurofibromatosis Type 1 Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Neurofibromatosis Type 1 Market

25.1. Canada Neurofibromatosis Type 1 Market Overview
25.2. Canada Neurofibromatosis Type 1 Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Neurofibromatosis Type 1 Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Neurofibromatosis Type 1 Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Neurofibromatosis Type 1 Market

26.1. South America Neurofibromatosis Type 1 Market Overview
26.2. South America Neurofibromatosis Type 1 Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Neurofibromatosis Type 1 Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Neurofibromatosis Type 1 Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Neurofibromatosis Type 1 Market

27.1. Brazil Neurofibromatosis Type 1 Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Neurofibromatosis Type 1 Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Neurofibromatosis Type 1 Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Neurofibromatosis Type 1 Market

28.1. Middle East Neurofibromatosis Type 1 Market Overview
28.2. Middle East Neurofibromatosis Type 1 Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Neurofibromatosis Type 1 Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Neurofibromatosis Type 1 Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Neurofibromatosis Type 1 Market

29.1. Africa Neurofibromatosis Type 1 Market Overview
29.2. Africa Neurofibromatosis Type 1 Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Neurofibromatosis Type 1 Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Neurofibromatosis Type 1 Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Neurofibromatosis Type 1 Market Competitive Landscape And Company Profiles

30.1. Neurofibromatosis Type 1 Market Competitive Landscape
30.2. Neurofibromatosis Type 1 Market Company Profiles
- 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. F. Hoffmann-La Roche Ltd Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. Merck & Co. Inc Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. AstraZeneca Plc Overview, Products and Services, Strategy and Financial Analysis

31. Neurofibromatosis Type 1 Market Other Major And Innovative Companies

31.1. Takeda Pharmaceutical Company Limited
31.2. Boehringer Ingelheim International GmbH
31.3. Vertex Pharmaceuticals Incorporated
31.4. Shanghai Fosun Pharmaceutical (Group) Co. Ltd
31.5. BeiGene Ltd.
31.6. BioMarin Pharmaceutical Inc
31.7. Exelixis Inc.
31.8. Blueprint Medicines Corporation
31.9. SpringWorks Therapeutics Inc
31.10. Onclive LLC
31.11. Healx Limited
31.12. Infixion Bioscience Limited
31.13. NFlection Therapeutics Inc
31.14. Pasithea Therapeutics Corporation
31.15. Mulberry Biotherapeutics Inc.

32. Global Neurofibromatosis Type 1 Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Neurofibromatosis Type 1 Market

34. Recent Developments In The Neurofibromatosis Type 1 Market

35. Neurofibromatosis Type 1 Market High Potential Countries, Segments and Strategies

35.1 Neurofibromatosis Type 1 Market In 2029 - Countries Offering Most New Opportunities
35.2 Neurofibromatosis Type 1 Market In 2029 - Segments Offering Most New Opportunities
35.3 Neurofibromatosis Type 1 Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations
36.2. Currencies
36.3. Historic And Forecast Inflation Rates
36.4. Research Inquiries
36.5. The Business Research Company
36.6. Copyright And Disclaimer